NCT00216073 - Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Capecitabine

Capecitabine 825 mg/m2 po bid, days 1-14

DRUG

Oxaliplatin

Oxaliplatin 100 mg/m2 IV, day 1

DRUG

Trastuzumab

Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.

Trial Locations (11)

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

Community Regional Cancer Center, Indianapolis

Elkhart Clinic, Elkhart

Northern Indiana Cancer Research Consortium, South Bend

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

Medical Consultants, P.C., Muncie

Cancer Care Center of Southern Indiana, Bloomington

AP&S Clinic, Terre Haute

Center for Hematology/Oncology of S. Michigan, Jackson

Medical & Surgical Specialists, LLC, Galesburg